复方新诺明（甲氧苄啶-磺胺甲恶唑）的临床药代动力学 - Suppr

Suppr

超能文献

Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

作者信息

Patel R B, Welling P G

出版信息

Clin Pharmacokinet. 1980 Sep-Oct;5(5):405-23. doi: 10.2165/00003088-198005050-00001.

DOI:10.2165/00003088-198005050-00001

PMID:7408366

Abstract

摘要

相似文献

Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).复方新诺明（甲氧苄啶-磺胺甲恶唑）的临床药代动力学

Clin Pharmacokinet. 1980 Sep-Oct;5(5):405-23. doi: 10.2165/00003088-198005050-00001.

Data on the pharmacokinetics of sulphamethoxazole and trimethoprim in buffalo calves.

Zentralbl Veterinarmed A. 1984 Feb;31(1):25-30. doi: 10.1111/j.1439-0442.1984.tb01259.x.

Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.

Diabet Med. 1987 May-Jun;4(3):245-7. doi: 10.1111/j.1464-5491.1987.tb00872.x.

[Clinical pharmacology of co-trimoxazole (biseptol)].

Postepy Hig Med Dosw. 1983 Sep-Dec;37(5-6):537-60.

[Technology and pharmacokinetics of sulfamethoxazole-trimethoprim suppositories].

Acta Pharm Hung. 1980 Nov;50(6):263-9.

Co-trimoxazole: kinetic differences and the route of administration.

J Antimicrob Chemother. 1977 Sep;3(5):528-9. doi: 10.1093/jac/3.5.528.

Concentrations of trimethoprim and sulphamethoxazole in the human prostate gland after intramuscular injection.

Br J Urol. 1982 Oct;54(5):550-1. doi: 10.1111/j.1464-410x.1982.tb13588.x.

The Pharmacokinetic profile of co-trimoxazole.

Scand J Infect Dis Suppl. 1976(8):42-9.

Evaluation of slow infusions of co-trimoxazole by using predictive pharmacokinetics.通过预测性药代动力学评估复方新诺明的缓慢输注。

Antimicrob Agents Chemother. 1980 Feb;17(2):132-7. doi: 10.1128/AAC.17.2.132.

[Role of the skin in the distribution of co-trimoxazole components].

Pol Tyg Lek. 1983 Mar 28;38(13):393-6.

引用本文的文献

Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.工程化结核分枝杆菌三重杀灭开关菌株在动物模型中实现了对结核病感染的可控性。

Nat Microbiol. 2025 Feb;10(2):482-494. doi: 10.1038/s41564-024-01913-5. Epub 2025 Jan 10.

Hyperkalemic effect of drug-drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study.依普利酮与甲氧苄啶药物相互作用对高血压患者的高钾血症影响：一项试点研究。

J Pharm Health Care Sci. 2024 Aug 2;10(1):46. doi: 10.1186/s40780-024-00366-6.

Sulfamethoxazole-induced crystal nephropathy: characterization and prognosis in a case series.磺胺甲恶唑相关性结晶肾病：病例系列研究中的特征和预后。

Sci Rep. 2024 Mar 13;14(1):6078. doi: 10.1038/s41598-024-56322-9.

Effective Treatments of UTI-Is Intravesical Therapy the Future?泌尿道感染的有效治疗方法——膀胱内灌注疗法是未来的发展方向吗？

Pathogens. 2023 Mar 6;12(3):417. doi: 10.3390/pathogens12030417.

Evaluation of treatment options for methicillin-resistant infections in the obese patient.肥胖患者耐甲氧西林感染治疗方案的评估。

Infect Drug Resist. 2019 Apr 17;12:877-891. doi: 10.2147/IDR.S196264. eCollection 2019.

Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.根据世界卫生组织指南，HIV感染儿童的复方新诺明预防性用药浓度未达最佳水平。

Br J Clin Pharmacol. 2017 Dec;83(12):2729-2740. doi: 10.1111/bcp.13397. Epub 2017 Sep 20.

Rhabdomyolysis due to Trimethoprim-Sulfamethoxazole Administration following a Hematopoietic Stem Cell Transplant.造血干细胞移植后服用甲氧苄啶-磺胺甲恶唑所致横纹肌溶解症。

Case Rep Oncol Med. 2015;2015:619473. doi: 10.1155/2015/619473. Epub 2015 Oct 18.

Cotrimoxazole - optimal dosing in the critically ill.复方新诺明——危重症患者的最佳给药剂量

Ann Intensive Care. 2014 Apr 28;4:13. doi: 10.1186/2110-5820-4-13. eCollection 2014.

Antibiograms from community-acquired uropathogens in Gulu, northern Uganda--a cross-sectional study.乌干达北部古卢社区获得性尿路感染病原体的抗生素药敏谱分析-一项横断面研究。

BMC Infect Dis. 2013 Apr 29;13:193. doi: 10.1186/1471-2334-13-193.

Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.细菌生物膜：后抗生素时代的发展、传播和治疗策略。

Cold Spring Harb Perspect Med. 2013 Apr 1;3(4):a010306. doi: 10.1101/cshperspect.a010306.

本文引用的文献

5-BENZYL-2,4-DIAMINOPYRIMIDINES AS ANTIBACTERIAL AGENTS. I. SYNTHESIS AND ANTIBACTERIAL ACTIVITY IN VITRO.5-苄基-2,4-二氨基嘧啶类抗菌剂。I. 体外合成与抗菌活性

J Med Pharm Chem. 1962 Nov;5:1103-23. doi: 10.1021/jm01241a004.

Trimethoprim resistance in Finland after five years' use of plain trimethoprim.在单纯使用甲氧苄啶五年后芬兰出现的甲氧苄啶耐药性。

Br Med J. 1980 Jan 12;280(6207):72-4. doi: 10.1136/bmj.280.6207.72.

Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.甲氧苄啶 - 磺胺甲恶唑与人消旋华法林分离对映体的立体选择性相互作用。

N Engl J Med. 1980 Jan 3;302(1):33-5. doi: 10.1056/NEJM198001033020106.

Sulfamethoxazole-trimethoprim synergism for Neisseria gonorrhoeae.磺胺甲恶唑-甲氧苄啶对淋病奈瑟菌的协同作用。

Antimicrob Agents Chemother. 1980 Feb;17(2):247-50. doi: 10.1128/AAC.17.2.247.

Resistance to trimethoprim and other antibiotics in Ontario shigellae.

Lancet. 1980 Feb 23;1(8165):426.

Resistance to trimethoprim and other antibiotics in Ontario shigellae.

Lancet. 1980 Feb 23;1(8165):425-6. doi: 10.1016/s0140-6736(80)90977-0.

Blood levels of drug at the equilibrium state after multiple dosing.多次给药后达到平衡状态时药物的血药浓度。

Nature. 1965 Sep 18;207(5003):1301-2. doi: 10.1038/2071301a0.

Trimethoprim: laboratory and clinical studies.甲氧苄啶：实验室研究与临床研究

J Clin Pathol. 1968 Mar;21(2):202-9. doi: 10.1136/jcp.21.2.202.

Trimethoprim metabolites in rat, dog and man: qualitative and quantitative studies.大鼠、犬和人体中的甲氧苄啶代谢产物：定性和定量研究。

Arzneimittelforschung. 1970 Dec;20(12):1867-71.

Pharmacokinetics of sulfamethoxazole plus trimethoprim in man and their distribution in the rat.磺胺甲恶唑加甲氧苄啶在人体中的药代动力学及其在大鼠体内的分布。

Chemotherapy. 1970;15(6):337-55. doi: 10.1159/000220701.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验